

Jenny H J Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1842046/publications.pdf>

Version: 2024-02-01

20
papers

1,369
citations

623734

14
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

2815
citing authors

#	ARTICLE	IF	CITATIONS
1	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Frontiers in Oncology</i> , 2022, 12, 820510.	2.8	2
2	Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103187.	4.4	17
3	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5926-5933.	7.0	41
4	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. <i>Cancers</i> , 2020, 12, 3374.	3.7	27
5	Dosing of BRAF and MEK Inhibitors in Melanoma: No Point in Taking a Break. <i>Cancer Cell</i> , 2020, 38, 779-781.	16.8	3
6	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020, 12, 2228.	3.7	22
7	Methylated circulating tumor DNA as a biomarker in cutaneous melanoma. <i>Melanoma Management</i> , 2020, 7, MMT46.	0.5	7
8	Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 378-383.e1.	2.6	8
9	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 4064-4071.	7.0	50
10	Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. <i>Nature Communications</i> , 2020, 11, 1897.	12.8	165
11	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 1905.	3.7	14
12	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1557-1563.	7.0	249
13	Monitoring Melanoma Using Circulating Free DNA. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 1-12.	6.7	26
14	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 223-258.	0.1	0
15	Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 404-410.	3.3	34
16	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. <i>JAMA Oncology</i> , 2018, 4, 717.	7.1	229
17	Evaluation of commercial kits for purification of circulating free DNA. <i>Cancer Genetics</i> , 2018, 228-229, 21-27.	0.4	90
18	Liquid biomarkers in melanoma: detection and discovery. <i>Molecular Cancer</i> , 2018, 17, 8.	19.2	74

#	ARTICLE	IF	CITATIONS
19	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. <i>Biomarker Research</i> , 2017, 5, 32.	6.8	33
20	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 42008-42018.	1.8	278